Sorrento Therapeutics Inc (SRNE) was Initiated by ROTH Capital to “Buy”. ROTH Capital advised their investors in a research report released on Oct 3, 2016.
Sorrento Therapeutics Inc opened for trading at $7.54 and hit $7.83 on the upside on Friday, eventually ending the session at $7.74, with a gain of 1.84% or 0.14 points. The heightened volatility saw the trading volume jump to 4,22,671 shares. Company has a market cap of $446 M.
In a different news, on Sep 21, 2015, George Uy (officer ) sold 47,500 shares at $0.00 per share price. According to the SEC, on Aug 26, 2015, Henry Ji (CEO) purchased 500 shares at $0.73 per share price. On Aug 21, 2015, George K Ng (officer ) purchased 888 shares at $13.46 per share price, according to the Form-4 filing with the securities and exchange commission.
Sorrento Therapeutics Inc. is a biopharmaceutical company. The Company is engaged in the discovery acquisition development and commercialization of drug therapeutics for addressing unmet medical needs in the United States Europe as well as international markets. Its primary therapeutic focus is oncology including the treatment of chronic cancer pain but it is also developing therapeutic products for other indications including immunology and infectious diseases. Its products in the pipeline include Cynviloq and resiniferatoxin (RTX) a non-opiate ultra-potent and selective agonist of the transient receptor potential cation channel subfamily V member 1 (TRPV-1) receptor. Its pipeline also includes preclinical human therapeutic monoclonal antibodies (mAbs) antibody drug conjugates (ADCs) bispecific antibodies (BsAbs) as well as Chimeric Antigen Receptor Tumor-attacking Neukoplast (CAR.TNK) for adoptive cellular immunotherapies (ACI).